Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

CFTR Modulator Use is Associated with Higher Hemoglobin Levels in Individuals with Cystic Fibrosis.

Gifford AH, Heltshe SL, Goss CH.

Ann Am Thorac Soc. 2018 Dec 22. doi: 10.1513/AnnalsATS.201807-449OC. [Epub ahead of print]

PMID:
30580531
2.

The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype.

Olson AL, Gifford AH, Inase N, Fernández Pérez ER, Suda T.

Eur Respir Rev. 2018 Dec 21;27(150). pii: 180077. doi: 10.1183/16000617.0077-2018. Print 2018 Dec 31. Review.

3.

Autoimmunity to bactericidal/permeability-increasing protein in bronchiectasis exhibits a requirement for Pseudomonas aeruginosa IgG response.

Skopelja-Gardner S, Theprungsirikul J, Meagher RE, Beliveau CM, Bradley KE, Avery M, Henkle E, Siegel S, Gifford AH, Winthrop KL, Rigby WFC.

Eur Respir J. 2019 Feb 7;53(2). pii: 1801891. doi: 10.1183/13993003.01891-2018. Print 2019 Feb. No abstract available.

PMID:
30385530
4.

Profiling of Bacterial and Fungal Microbial Communities in Cystic Fibrosis Sputum Using RNA.

Grahl N, Dolben EL, Filkins LM, Crocker AW, Willger SD, Morrison HG, Sogin ML, Ashare A, Gifford AH, Jacobs NJ, Schwartzman JD, Hogan DA.

mSphere. 2018 Aug 8;3(4). pii: e00292-18. doi: 10.1128/mSphere.00292-18.

5.

Complications of long and intermediate term venous catheters in cystic fibrosis patients: A multicenter study.

May TL, Gifford AH, Lahiri T, Black A, Trang J, Cornell AG, Gonzalez K, Morin S, Napier M, Duarte CW, Zuckerman JB.

J Cyst Fibros. 2018 Jan;17(1):96-104. doi: 10.1016/j.jcf.2017.04.014. Epub 2017 Jun 2.

PMID:
28579360
6.

The role for neutrophil extracellular traps in cystic fibrosis autoimmunity.

Skopelja S, Hamilton BJ, Jones JD, Yang ML, Mamula M, Ashare A, Gifford AH, Rigby WF.

JCI Insight. 2016 Oct 20;1(17):e88912.

7.

Use of a Multiplex Transcript Method for Analysis of Pseudomonas aeruginosa Gene Expression Profiles in the Cystic Fibrosis Lung.

Gifford AH, Willger SD, Dolben EL, Moulton LA, Dorman DB, Bean H, Hill JE, Hampton TH, Ashare A, Hogan DA.

Infect Immun. 2016 Sep 19;84(10):2995-3006. doi: 10.1128/IAI.00437-16. Print 2016 Oct.

8.

Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).

Mahler DA, Gifford AH, Satti A, Jessop N, Eckert JH, D'Andrea P, Mota F, Banerjee R.

Respir Med. 2016 Jun;115:39-45. doi: 10.1016/j.rmed.2016.03.015. Epub 2016 Mar 22.

9.

Serum Iron Level Is Associated with Time to Antibiotics in Cystic Fibrosis.

Gifford AH, Dorman DB, Moulton LA, Helm JE, Griffin MM, MacKenzie TA.

Clin Transl Sci. 2015 Dec;8(6):754-8. doi: 10.1111/cts.12358. Epub 2015 Dec 8.

10.

Noninvasive Ventilation Plus Extracorporeal CO2 Removal in High-Risk Conditions: A Forthcoming Tool?

Esquinas AM, Peris A, Gifford AH.

Crit Care Med. 2015 Sep;43(9):e390. doi: 10.1097/CCM.0000000000001066. No abstract available.

PMID:
26274722
11.

Prospective use of descriptors of dyspnea to diagnose common respiratory diseases.

Chang AS, Munson J, Gifford AH, Mahler DA.

Chest. 2015 Oct;148(4):895-902. doi: 10.1378/chest.15-0308.

PMID:
25905554
12.

Failure of high-flow nasal cannula and delayed intubation: a new harmful sequence?

Esquinas AM, Parke R, Gifford AH.

Intensive Care Med. 2015 Jun;41(6):1170. doi: 10.1007/s00134-015-3804-3. Epub 2015 Apr 24. No abstract available.

PMID:
25904182
13.

Quality of dying in the intensive care unit: it's a matter of time.

Gifford AH, Esquinas AM.

Intensive Care Med. 2014 Nov;40(11):1792. doi: 10.1007/s00134-014-3499-x. Epub 2014 Oct 7. No abstract available.

PMID:
25288209
14.

Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry.

MacKenzie T, Gifford AH, Sabadosa KA, Quinton HB, Knapp EA, Goss CH, Marshall BC.

Ann Intern Med. 2014 Aug 19;161(4):233-41. doi: 10.7326/M13-0636.

15.

The microbiome in pediatric cystic fibrosis patients: the role of shared environment suggests a window of intervention.

Hampton TH, Green DM, Cutting GR, Morrison HG, Sogin ML, Gifford AH, Stanton BA, O'Toole GA.

Microbiome. 2014 Apr 28;2:14. doi: 10.1186/2049-2618-2-14. eCollection 2014.

16.

Noninvasive ventilation as a palliative measure.

Gifford AH.

Curr Opin Support Palliat Care. 2014 Sep;8(3):218-24. doi: 10.1097/SPC.0000000000000068. Review.

PMID:
24978145
17.

What is hepcidin telling us about the natural history of cystic fibrosis?

Gifford AH.

J Cyst Fibros. 2015 Jan;14(1):155-7. doi: 10.1016/j.jcf.2014.03.012. Epub 2014 Apr 30. No abstract available.

18.

Antagonism of substance P and perception of breathlessness in patients with chronic obstructive pulmonary disease.

Mahler DA, Gifford AH, Gilani A, Waterman LA, Hilton J, Chang AS, Kupchak BR, Kraemer WJ.

Respir Physiol Neurobiol. 2014 Jun 1;196:1-7. doi: 10.1016/j.resp.2014.02.008. Epub 2014 Feb 25.

PMID:
24582719
19.

Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation.

Price KE, Hampton TH, Gifford AH, Dolben EL, Hogan DA, Morrison HG, Sogin ML, O'Toole GA.

Microbiome. 2013 Nov 1;1(1):27. doi: 10.1186/2049-2618-1-27.

20.

Iron supplementation does not worsen respiratory health or alter the sputum microbiome in cystic fibrosis.

Gifford AH, Alexandru DM, Li Z, Dorman DB, Moulton LA, Price KE, Hampton TH, Sogin ML, Zuckerman JB, Parker HW, Stanton BA, O'Toole GA.

J Cyst Fibros. 2014 May;13(3):311-8. doi: 10.1016/j.jcf.2013.11.004. Epub 2013 Dec 13.

21.

Hemoglobin ≤ 12.9 g/dl predicts risk of antibiotic treatment in cystic fibrosis.

Gifford AH.

J Cyst Fibros. 2014 Jan;13(1):114-5. doi: 10.1016/j.jcf.2013.06.007. Epub 2013 Jul 16. No abstract available.

22.

Serum insulin-like growth factor-1 (IGF-1) during CF pulmonary exacerbation: trends and biomarker correlations.

Gifford AH, Nymon AB, Ashare A.

Pediatr Pulmonol. 2014 Apr;49(4):335-41. doi: 10.1002/ppul.22822. Epub 2013 Jun 18.

23.

Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.

Mahler DA, Waterman LA, Ward J, Gifford AH.

J Aerosol Med Pulm Drug Deliv. 2014 Apr;27(2):103-9. doi: 10.1089/jamp.2013.1038. Epub 2013 Jun 8.

PMID:
23745526
24.

Effect of increased blood levels of β-endorphin on perception of breathlessness.

Mahler DA, Gifford AH, Waterman LA, Ward J, Kraemer WJ, Kupchak BR, Harver A.

Chest. 2013 May;143(5):1378-1385. doi: 10.1378/chest.12-1541.

PMID:
23715032
25.

Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler.

Mahler DA, Waterman LA, Gifford AH.

J Aerosol Med Pulm Drug Deliv. 2013 Jun;26(3):174-9. doi: 10.1089/jamp.2012.0987. Epub 2012 Oct 1.

PMID:
23025451
26.

Iron homeostasis during cystic fibrosis pulmonary exacerbation.

Gifford AH, Moulton LA, Dorman DB, Olbina G, Westerman M, Parker HW, Stanton BA, O'Toole GA.

Clin Transl Sci. 2012 Aug;5(4):368-73. doi: 10.1111/j.1752-8062.2012.00417.x. Epub 2012 Jun 1.

27.

Chronic inflammation and lung fibrosis: pleotropic syndromes but limited distinct phenotypes.

Gifford AH, Matsuoka M, Ghoda LY, Homer RJ, Enelow RI.

Mucosal Immunol. 2012 Sep;5(5):480-4. doi: 10.1038/mi.2012.68. Epub 2012 Jul 18. Review.

PMID:
22806097
28.

Prevalence of streptococci and increased polymicrobial diversity associated with cystic fibrosis patient stability.

Filkins LM, Hampton TH, Gifford AH, Gross MJ, Hogan DA, Sogin ML, Morrison HG, Paster BJ, O'Toole GA.

J Bacteriol. 2012 Sep;194(17):4709-17. doi: 10.1128/JB.00566-12. Epub 2012 Jun 29.

29.

Neuromodulatory effect of endogenous opioids on the intensity and unpleasantness of breathlessness during resistive load breathing in COPD.

Gifford AH, Mahler DA, Waterman LA, Ward J, Kraemer WJ, Kupchak BR, Baird JC.

COPD. 2011 Jun;8(3):160-6. doi: 10.3109/15412555.2011.560132. Epub 2011 Apr 22.

PMID:
21513438
30.

Mechanism of greater oxygen desaturation during walking compared with cycling in patients with COPD.

Mahler DA, Gifford AH, Waterman LA, Ward J, Machala S, Baird JC.

Chest. 2011 Aug;140(2):351-358. doi: 10.1378/chest.10-2415. Epub 2011 Jan 27.

PMID:
21273296
31.

Iron and CF-related anemia: expanding clinical and biochemical relationships.

Gifford AH, Miller SD, Jackson BP, Hampton TH, O'Toole GA, Stanton BA, Parker HW.

Pediatr Pulmonol. 2011 Feb;46(2):160-5. doi: 10.1002/ppul.21335. Epub 2010 Oct 20.

32.

Respiratory function in an obese patient with sleep-disordered breathing.

Gifford AH, Leiter JC, Manning HL.

Chest. 2010 Sep;138(3):704-15. doi: 10.1378/chest.09-3030. No abstract available.

PMID:
20822992
33.

An unusual cause of endobronchial obstruction.

Gifford AH, Matsuoka M, Schwartzman JD.

Respiration. 2009;78(4):460-4. doi: 10.1159/000235549. Epub 2009 Aug 12. No abstract available.

PMID:
19672056
34.

Risk factors for Clostridium difficile-associated diarrhea on an adult hematology-oncology ward.

Gifford AH, Kirkland KB.

Eur J Clin Microbiol Infect Dis. 2006 Dec;25(12):751-5.

PMID:
17072575
35.
36.

Serum stimulates growth of and proteinase secretion by Aspergillus fumigatus.

Gifford AH, Klippenstein JR, Moore MM.

Infect Immun. 2002 Jan;70(1):19-26.

37.

Aneurysm of the Superior Mesenteric Artery, with Rupture.

Gifford AH.

Br Med J. 1912 Jun 29;1(2687):1478-9. No abstract available.

Supplemental Content

Loading ...
Support Center